Business Trip
61 episodes - English - Latest episode: 24 days ago -Business Trip tells the story of businesses at the frontier of mental health and wellness. Each episode features founders, investors, and researchers in psychedelics, neurotechnology, metabolic psychiatry, digital therapeutics, and more.
Homepage Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
FDA advisors say no to MDMA. What’s the impact? With Josh Hardman
June 21, 2024 12:00 - 56 minutes - 39.1 MBGreg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD. Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting. In this episode, we discuss: The FDA advisory committee process and its implications for drug approvals Functional unblinding and expectancy effects in psyched...
Investing in New Frontiers of Mental Health (Live at SXSW)
May 07, 2024 16:00 - 50 minutes - 34.8 MBSoftware, hardware, and biotechnology are playing an increasingly transformative role in our mental health and wellness. Join us as we discuss what investors look for in these new companies and how they separate what’s real — and what’s near-term — from what’s hype. We’ll explore AI-powered tools for mental health, the new area of “enerceuticals” (energy replacing the “pharma”), psychedelics, and why what’s in your gut is so important to your mental state. Hear from investors who have a wide...
Chemical Conversations: Comparing Psychedelic Compounds in Therapy
April 09, 2024 15:00 - 1 hour - 42.6 MBMatias hosted a panel at The Battery SF with renowned psychedelics experts, Nolan Williams, Allison Feduccia, Matt Baggott. Nolan is a Stanford professor currently researching ibogaine among other areas in psychiatry and radiology, and he's a founder of TMS company Magnus Medical. Allison is the founder of Psychedelic Support, a platform providing psychedelic education, community and a provider directory. And Matt is founder and CEO of Tactogen, a biotech company developing compounds simila...
Comparing Psychedelic Compounds in Therapy (Live Panel at Battery SF)
April 09, 2024 15:00 - 1 hour - 42.6 MBMatias hosted a panel at The Battery SF with renowned psychedelics experts, Nolan Williams, Allison Feduccia, Matt Baggott. Nolan is a Stanford professor currently researching ibogaine among other areas in psychiatry and radiology, and he's a founder of TMS company Magnus Medical. Allison is the founder of Psychedelic Support, a platform providing psychedelic education, community and a provider directory. And Matt is founder and CEO of Tactogen, a biotech company developing compounds simila...
What Payers Want with Lili Brillstein
March 14, 2024 17:00 - 48 minutes - 33.3 MBMatias interviews Lili Brillstein about how to work collaboratively with healthcare payers (the ones that reimburse for medical expenses). Lili is a pioneer in the field, having previously led one of the largest bundled payment initiatives at Horizon Blue Cross Blue Shield. She currently is the founder of her own advisory firm, BCollaborative, where she helps startups and providers develop value propositions that resonate with payers and create models that can be successfully administered. ...
Decoding the Brain with Ed Boyden
February 22, 2024 17:00 - 50 minutes - 34.9 MBGreg and Matias interview Ed Boyden about neuroscience frontiers and its applications to mental health. Ed is a pioneer in understanding the fundamental mechanisms of the brain. He runs a lab at MIT for Synthetic Neurobiology and is a professor across the departments of neurotechnology, biological engineering, and cognitive science at MIT’s McGovern Institute for Brain Research. His inventions include optogenetic tools and expansion microscopy. He is co-founder of Cognito Therapeutics, Elem...
5-MeO-DMT in mental healthcare with Steve Rio
January 25, 2024 17:00 - 50 minutes - 34.7 MBGreg and Matias interview Steve Rio about 5-MeO-DMT and its potential role in mental healthcare. Steve is a social impact cofounder, transformational coach, and practitioner at the Enfold Institute, one of the most reputable aboveground retreat centers working with 5-MeO-DMT. He shared many insights from his hands-on experience guiding hundreds of people through the medicine. In this episode, we discuss… 5-MeO-DMT’s distinct psychedelic experience Enfold’s protocol of screening, prepara...
Tom Insel: Startups, AI, Psychedelics, and SSRIs
December 15, 2023 13:00 - 57 minutes - 39.8 MBTom Insel is an entrepreneur and former director of the US National Institute of Mental Health, the lead US agency supporting mental health research with a $2 billion budget. Since his time at the NIMH, Tom has built mental health technology, first at Verily and Mindstrong Health, and more recently founded Vanna Health, an online healthcare provider for serious mental illness. In his book "Healing", he talks about the importance of the 3 P's for solving the US mental health crisis: People, ...
Food as Medicine for Mental Health: Drew Ramsey
November 30, 2023 17:00 - 46 minutes - 31.9 MBWhat if your next antidepressant was a clam or spinach? Greg & Matias invite Dr. Drew Ramsey to explore nutritional psychiatry - a field exploring how the food we eat can be as powerful as medication in treating mental illnesses like depression and anxiety. Dr. Drew Ramsey is a psychiatrist, entrepreneur and author focusing on nutritional interventions for mental wellbeing. Drew shares scientific research to make a business case for nutritional psychiatry - how customized food intervention...
Ketogenic Diet for Brain Health: Jan Baszucki
November 16, 2023 17:00 - 44 minutes - 30.5 MBCan diet treat mental illness? Greg and Matias interview Jan Baszucki of the Baszucki Group whose son Matt overcame bipolar through the ketogenic diet. Jan has supported studies on ketogenic diets and fasting protocols for conditions like depression, schizophrenia, and bipolar disorder. In this episode we discuss: The powerful personal story behind Jan's passion for this field The science and mechanistic details behind metabolic psychiatry Misconceptions about mental health and diets ...
Investing in Neurotech 101: Alex Morgan of Khosla Ventures
November 02, 2023 16:00 - 54 minutes - 37.6 MBAdvancements in neuroscience, AI, and bioengineering are unlocking new possibilities for neurotechnologies. Investors are paying attention. Alex Morgan of Khosla Ventures is an MD, PhD, physicist, and one of the most active investors in neurotech startups. He's backed companies harnessing neuromodulation for varied applications - from sleep (Somnee) to depression (Flow) to motor recovery (Syncron). In this episode, Alex shares an insider's overview of the neurotech landscape. We discuss w...
All you need is d̶r̶u̶g̶s̶ energy: Motif Neurotech's Implants for Depression
October 20, 2023 16:00 - 55 minutes - 37.8 MBNeuromodulation flies in the face of modern psychiatry. It can significantly improve mental health without drugs. It allows us to stimulate or inhibit activity in precise regions of the brain using electricity, magnetism or ultrasound. Motif Neurotech is pioneering minimally invasive implants to precisely deliver neuromodulation for mental health. In this special episode, Matias joins Empath Ventures’ Brom Rector to interview Jacob Robinson, an entrepreneurial scientist who leveraged his a...
Holy shit! Mental health and the gut (part 2 with Bloom Science)
September 28, 2023 15:00 - 40 minutes - 27.7 MBIn part 2 of a 2-part series, Greg and Matias explore microbial therapeutics for mental health with Dr. Christopher Reyes, biophysist, serial enterepreneur, and founder of Bloom Science. Dr. Reyes' research on leveraging microbes to treat neurological conditions began at UC San Francisco. He is now translating his microbiome research into startups targeting epilepsy, ALS, and even anxiety and depression. We discuss the science behind how gut microbes may influence neurotransmitters and mood...
Holy poop! Mental health and the gut (part 2 with Bloom Science)
September 28, 2023 15:00 - 40 minutes - 27.7 MBIn part 2 of a 2-part series, Greg and Matias explore microbial therapeutics for mental health with Dr. Christopher Reyes, biophysist, serial enterepreneur, and founder of Bloom Science. Dr. Reyes' research on leveraging microbes to treat neurological conditions began at UC San Francisco. He is now translating his microbiome research into startups targeting epilepsy, ALS, and even anxiety and depression. We discuss the science behind how gut microbes may influence neurotransmitters and mood...
Holy poop! Mental health and the gut (part 1 with Holobiome)
September 14, 2023 17:00 - 48 minutes - 33.6 MBBusiness Trip launched in 2020 as a podcast focused on psychedelics. As Matias and Greg started to dive deeper into the complexities of mental health, they met more and more entrepreneurs and scientists creating novel treatments across many areas of mental health, including the gut microbiome. Dr. Phil Strandwitz pulls back the curtain on the gut-brain connection and the future of mental health. As founder of Holobiome, Phil is pioneering microbial therapies for conditions like depression ...
Holy shit! Mental health and the gut (part 1 with Holobiome)
September 14, 2023 17:00 - 48 minutes - 33.6 MBBusiness Trip launched in 2020 as a podcast focused on psychedelics. As Matias and Greg started to dive deeper into the complexities of mental health, they met more and more entrepreneurs and scientists creating novel treatments across many areas of mental health, including the gut microbiome. Dr. Phil Strandwitz pulls back the curtain on the gut-brain connection and the future of mental health. As founder of Holobiome, Phil is pioneering microbial therapies for conditions like depression ...
Ketamine for OCD: Carolyn Rodriguez (Stanford pt 3)
August 24, 2023 15:00 - 38 minutes - 26.5 MBStanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. This is part 3 of a 3-part series, where we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We conclude the series with Carolyn Rodriguez. Carolyn Rodriguez is Associate Dean at Stanford University School of Medicine and a psychiatrist at the Palo Al...
Stanford Psychedelics: Carolyn Rodriguez
August 24, 2023 15:00 - 38 minutes - 26.5 MBStanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. This is part 3 of a 3-part series, where we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We conclude the series with Carolyn Rodriguez. Carolyn Rodriguez is Associate Dean at Stanford University School of Medicine and a psychiatrist at the Palo Al...
Are psychedelics effective under anesthesia?: Boris Heifets (Stanford pt 2)
August 17, 2023 15:00 - 37 minutes - 25.8 MBStanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. This is part 2 of a 3-part series, where we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We continue with Boris Heifets. Boris Heifets, an assistant professor at Stanford's School of Medicine. Boris leads the Heifets Lab, which is dedicated to und...
Stanford Psychedelics: Boris Heifets
August 17, 2023 15:00 - 37 minutes - 25.8 MBStanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. This is part 2 of a 3-part series, where we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We continue with Boris Heifets. Boris Heifets, an assistant professor at Stanford's School of Medicine. Boris leads the Heifets Lab, which is dedicated to und...
The Startup Landscape for Expanding Consciousness
August 09, 2023 18:00 - 1 hour - 55.8 MBPsychedelics have long been known to induce altered states of consciousness. But there are many other techniques that can also expand our awareness - from meditation and breathwork to exploring dreams, prayer, light and sound. In this episode, Greg speaks with Scott Britton about the emerging startup landscape around tools for expanding consciousness. Scott is an entrepreneur who now writes a newsletter called Consciousness ∞ The Doorway to Human Evolution He also hosts a podcast called Evo...
Stanford Psychedelic Overview: Robert Malenka (Stanford pt 1)
July 20, 2023 16:00 - 51 minutes - 35.3 MBStanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. In this 3-part series, we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We start the series with Robert Malenka. Robert Malenka is a professor of psychiatry at Stanford University with over three decades of experience in preclinical neuroscience re...
Stanford Psychedelics: Robert Malenka
July 20, 2023 16:00 - 51 minutes - 35.3 MBStanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. In this 3-part series, we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We start the series with Robert Malenka. Robert Malenka is a professor of psychiatry at Stanford University with over three decades of experience in preclinical neuroscience re...
Live from Psychedelic Science 2023
July 07, 2023 15:00 - 56 minutes - 39 MBPsychedelic Science 2023, Learning Man, MAPS Burn...whatever you want to call it...was a magical conference organized by MAPS. 12k people made the pilgrimage to Denver to discuss psychedelic science, culture, business, art, spirituality, and more. Rick Doblin called this the "Psychedelic 20's" and this event felt like a watershed moment. Luckily, Greg brought his microphone and recorded his experience for a special episode of Business Trip. Guests include Zach Haigney, Myriam Barthes, La...
What VCs Look for in Psychedelic Companies
June 09, 2023 14:00 - 41 minutes - 28.9 MBWhat does it take for a traditional VC to fund a psychedelic company? In our latest episode, Matias takes us behind the scenes of a panel discussion at the Psychedelic Therapeutics & Drug Development Conference in San Francisco, CA. Matias talks with VCs at firms with $100M+ fund sizes: Anne Dwane, a partner at Village Global, Amanda Way, principal at Jazz Venture Partners and Dana Watt PhD, principal at Breakout Ventures. In this episode, we discuss: (1) How VCs identify and evaluate a str...
Developing Non-Hallucinogenic Psychedelics: Bryan Roth
May 15, 2023 16:00 - 49 minutes - 34.3 MBIn our latest episode, Greg and Matias engage in an insightful discussion with Dr. Bryan Roth, the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine, and the founder of the Roth Lab. Dr. Roth’s lab is on the cutting edge of researching the interaction between brain cell receptors and compounds like LSD and psilocybin. Their findings have the potential to revolutionize the treatment of psychiatric disorders, potentially ...
Behind the Scenes of PsyMed Ventures
April 14, 2023 16:00 - 35 minutes - 24.6 MBIn this week's episode, Greg and Matias take a moment to reflect on the opportunities and challenges they have faced while building the PsyMed Ventures syndicate and venture capital fund since starting the Business Trip podcast in 2020. Their ultimate goal is to support founders who are building ethical businesses in frontier mental health technologies with the aim of ending the suffering caused by mental illnesses. This conversation offers an honest insight into raising and deploying a vent...
The 2023 Psychedelic Industry Landscape with Psychedelic Alpha
February 27, 2023 17:00 - 49 minutes - 34.3 MBIn this week’s episode, Greg and Matias chat with Josh Hardman, the founder of Psychedelic Alpha. Josh is a leading writer and founder at Psychedelic Alpha, an online resource, newsletter, and community covering the intersection of psychedelics and business. He regularly collaborates and writes with experts in the psychedelic field including entrepreneurs, academic researchers, non-profits, and more to provide a comprehensive understanding of the latest developments in the industry. Psyche...
The State of Psychedelics (Part 2): Dr. Rachel Yehuda and Zach Haigney (live recording at Soho House)
January 18, 2023 18:00 - 53 minutes - 37.1 MBIn this week’s special episode, Matias chats with Dr. Rachel Yehuda and Zach Haigney at Soho House in New York City. This is part 2 of a moderated panel recorded in front of a live audience, with part 1 released in June 2022. Dr. Yehuda has spent the last 30 years doing research on PTSD and trauma and is leading the MDMA-assisted therapy research at the US Veterans Affairs Medical Center and serves as Director at the Mental Health at the James J. Peters VA Medical Center. She is also the D...
The quest to improve MDMA
December 20, 2022 20:00 - 55 minutes - 38.1 MBThis episode shares the story of Tactogen, a drug development company making new chemical entities inspired by MDMA. Co-founder Matt Baggott has been fascinated by MDMA and has studied it for 30 years. And while he believes that MDMA can be effective as a therapeutic, his company is developing an MDMA analogue that is designed to be gentler and safer, with the potential to be administered in an at-home setting. Links: Tactogen WeFunder: https://wefunder.com/tactogen Credits: Created by...
Transcranial magnetic stimulation (TMS) paired with ketamine: inside a clinic offering a frontier treatment
November 29, 2022 16:00 - 50 minutes - 34.4 MBIn this new episode of Business Trip, we interview one of the first clinics to offer a protocol that includes TMS (transcranial magnetic stimulation) and ketamine infusion. TMS is a non-invasive procedure that sends electric currents to specific regions in the brain, including areas linked to depression. It's FDA approved and has been gaining adoption as clinical studies demonstrate safety and efficacy in treating mood disorders. So why the combination? TMS takes a local approach while ket...
Perspectives from Christian Angermayer, investor and founder in psychedelics
October 27, 2022 19:00 - 42 minutes - 29.3 MBIn this week's episode, we chat with Christian Angermayer. Christian co-founded atai Life Sciences and was an early investor in Compass Pathways -- two of the first companies commercializing psychedelic medicine. Christian also launched a fund dedicated to mental and neurological health called re:Mind, is an investor through his family office Apeiron, and co-founded two longevity biotech companies. Credits: Created by Greg Kubin and Matias Serebrinsky Host: Greg Kubin and Matias Serebrin...
Soltara: an ethical and profitable ayahuasca retreat
September 14, 2022 23:00 - 54 minutes - 37.6 MBIn this week’s episode, we chat with Melissa Stangl, co-founder of Soltara Healing Center. Soltara is an ayahuasca retreat center whose ceremonies are lead by Shipibo healers, with locations in Peru and Costa Rica. The Shipibo people are from the Peruvian Amazon and are part of a tradition that has been drinking Ayahuasca for healing and spiritual purposes for thousands of years. In their ceremonies, the Shipibo serve ayahuasca and sing songs, called Icaros, which guide the healing process a...
Microdosing (part 3): The path to FDA approval w/ MindMed and Diamond Therapeutics
August 16, 2022 16:00 - 58 minutes - 40.2 MBThis is final episode in our 3-part series on microdosing that explores the science, history, and clinical applications. In this episode, we discuss the path to FDA approval for microdosing. We chat with the chief medical officers from Diamond Therapeutics and MindMed about their microdosing clinical programs. Diamond's program uses synthetic psilocybin and is focused on anxiety disorders. Meanwhile, MindMed is focused using low doses of LSD to treat adult ADHD. Our guests are Dr. Michael...
Microdosing (part 2): Placebo is a hell of a drug with Balázs Szigeti
August 10, 2022 19:00 - 37 minutes - 25.8 MBThis is part 2 or our 3 part series on microdosing that explore the science, history, and clinical applications. In part 1, we interviewed psychedelic researcher James Fadiman about the fundamentals of microdosing. In part 2, we wanted to understand the placebo effect. In particular, is it the microdose that makes people feel better or it is a placebo effect? We interviewed Balázs Szigeti PhD, who is a researcher associate at the Centre for Psychedelic Research at Imperial College London. ...
Microdosing (part 2): The placebo effect with Balázs Szigeti
August 10, 2022 19:00 - 37 minutes - 25.8 MBThis is part 2 or our 3 part series on microdosing that explore the science, history, and clinical applications. In part 1, we interviewed psychedelic researcher James Fadiman about the fundamentals of microdosing. In part 2, we wanted to understand the placebo effect. In particular, is it the microdose that makes people feel better or it is a placebo effect? We interviewed Balázs Szigeti PhD, who is a researcher associate at the Centre for Psychedelic Research at Imperial College London. ...
Microdosing (part 1): James Fadiman and the fundamentals of microdosing
August 03, 2022 15:00 - 33 minutes - 22.8 MBIn this 3-part series on microdosing, we explore the science, history, and its clinical potential. The anecdotal benefits of microdosing include better mood, creativity, and increased focus. But there are still many unanswered questions that remain. What is an effective dosing protocol? Is it safe in long term use? Does it even work or is it a placebo effect? In part 1, we chat with James Fadiman, Ph.D who has been researching psychedelics since the 1960’s. He's the author of several book...
How the DEA and FDA will regulate psychedelic medicine
June 24, 2022 14:00 - 48 minutes - 33.6 MBIn this week’s episode, we chat with Matt Zorn, an attorney at Yetter Coleman with expertise in DEA law, especially regarding psychedelics. Matt is currently challenging the DEA’s decision to schedule 5 new tryptamines, he recently argued Kathryn Tucker’s psilocybin “Right To Try” case against the DEA, and previously co-led Sue Sisley’s DEA case related to cannabis scheduling. Matt also writes the drug policy newsletter On Drugs. Credits: Created by Greg Kubin and Matias Serebrinsky Host:...
The state of psychedelics: Dr. Rachel Yehuda and Zach Haigney (live recording at Soho House)
June 05, 2022 14:00 - 45 minutes - 31.5 MBIn this week’s special episode, Matias chats with Dr. Rachel Yehuda and Zach Haigney at Soho House in New York City. The episode was recorded in front of a live audience. Dr. Yehuda has spent the last 30 years doing research on PTSD and trauma and is leading the MDMA-assisted therapy research at the US Veterans Affairs Medical Center. She is the Director at the Mental Health Patient Care Center at the James J. Peters VA Medical Center, Director of the Center for Psychedelic Psychotherapy an...
Empowering the next wave of psychedelic therapists: Journey Clinical
May 23, 2022 04:00 - 41 minutes - 28.7 MBIn Episode 18, we chat with Jonathan Sabbagh and Myriam Barthes, the co-founders of Journey Clinical, a platform that enables licensed therapists to offer ketamine-assisted psychotherapy (KAP). Journey Clinical provides licensed therapists with an on-demand KAP-trained medical team, customized treatments for each client, and a portal to connect with other therapists and educational resources. In this episode, we discuss: The journey from idea to 100+ therapist members How ketamine-assiste...
Osmind and the future of electronic health records in psychedelic medicine
April 18, 2022 21:00 - 36 minutes - 25 MBIn today’s episode, we chat with Lucia Huang, the CEO and co-founder of Osmind, an electronic health record software system for treatment resistant mental health practices that is already in over 300 clinics. In this episode, we discuss: How Osmind makes data-driven decisions Osmind’s quick growth in only 2 years What it will take for insurance to cover ketamine therapy, as well as other psychedelic therapies Created by Greg Kubin and Matias Serebrinsky Host: Matias Serebrinsky & Greg...
Palo Santo on investing in 2nd gen psychedelics and public markets
March 21, 2022 21:00 - 48 minutes - 33.2 MBIn today’s episode, we chat with Tim Schlidt, a partner at Palo Santo. Palo Santo is a fund investing in psychedelic therapeutics. Palo Santo’s portfolio includes companies like Eleusis, Tactogen, and Journey Clinical. In this episode, we discuss: Tim’s background in healthcare finance Investing in classic psychedelic compounds vs. 2nd generation compounds Hallmarks of a good first meeting with a prospective investment Created by Greg Kubin and Matias Serebrinsky Host: Matias Serebrinsk...
Designing psychedelic mindstates, with Mindstate Design Labs
February 10, 2022 06:00 - 56 minutes - 39 MBToday’s episode features Dillan Dinardo and Tom Ray, the co-founders of Mindstate Design Labs. Mindstate has a unique framework to design psychedelic compounds using what they call the “primer probe method.” This method involves combining a known psychedelic with a non-psychedelic compound. Mindstate just raised an $11.5M seed round. In this episode, we discuss: Tom and Dillan’s experience in YCombinator and raising an $11.5M seed round Tom’s friendship with the late psychedelic chemist A...
PsyMed Ventures, our $25M fund to invest in psychedelic medicine & mental health tech
January 10, 2022 06:00 - 43 minutes - 29.7 MBToday’s episode announces the launch of PsyMed Ventures, a $25M fund we started with Dina Burkitbayeva to invest in psychedelic medicine companies and mental health technologies. PsyMed Ventures is a community-focused fund and syndicate providing capital and support to companies revolutionizing how mental health is treated. In this episode, we discuss: $25M fund to invest in psychedelic medicine companies and mental health tech How we evaluate new companies Exciting trends in mental heal...
PsyMed Ventures, our venture fund to invest in psychedelic medicine & mental health tech
January 10, 2022 06:00 - 43 minutes - 29.7 MBToday’s episode announces the launch of PsyMed Ventures, a $25M fund we started with Dina Burkitbayeva to invest in psychedelic medicine companies and mental health technologies. PsyMed Ventures is a community-focused fund and syndicate providing capital and support to companies revolutionizing how mental health is treated. In this episode, we discuss: $25M fund to invest in psychedelic medicine companies and mental health tech How we evaluate new companies Exciting trends in mental heal...
MAPS PBC, rethinking the pharma business model and MDMA-assisted therapy
November 24, 2021 06:00 - 51 minutes - 35.6 MBToday’s episode features Amy Emerson, the CEO of MAPS Public Benefit Corporation (PBC), which is a fully owned subsidiary of MAPS, and its purpose is to commercialize MDMA-assisted therapy. We discuss the MAPS PBC and it’s business model for MDMA-assisted therapy. In this episode, we discuss: MAPS’ protocol and strategy behind FDA clinical trial for PTSD Amy’s views on the state of the industry, patents, and how to prioritize accessibility The unique business model between MAPS and MAPS ...
On transformational ketamine therapy and running an integrative psychedelic clinic
October 28, 2021 05:00 - 1 hour - 43.7 MBIn today’s episode, we discuss what it’s like being a psychologist who owns a psychedelic clinic. Genesee Herzberg is the co-founder of Sage Integrative Health, an integrative clinic in Berkeley, CA that offers ketamine-assisted therapy (KAP), psychotherapy, somatic therapy, and acupuncture. Genesee discusses her holistic approach to healing, and shares her experience bootstrapping her clinic and setting up a non-profit to make KAP more affordable. In this episode, we discuss: Ketamine-ass...
The new frontiers of DMT therapies
October 06, 2021 20:00 - 42 minutes - 29 MBIn today’s episode, we explore the therapeutic application of DMT across a range of diseases and conditions including Alzheimer’s, stroke, and organ transplants. While much of the attention in psychedelic medicine has been on their ability to address neuropsychiatric indications, research suggests that psychedelics like DMT have a far wider therapeutic potential. The episode features three biotech companies developing DMT therapies: Algernon, Psilera, and Pharmadrug. In this episode, we di...
Scaling Psilocybin Therapy: Compass Pathways' Lars Wilde
August 13, 2021 17:00 - 59 minutes - 41.2 MBEpisode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways, a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression. In this episode, we discuss: Lars’ experience overcoming Treatment-Resistant Depression with psilocybin The nuances of clinical trials and psilocybin dosing protocols Compass Pathways’ Intellectual Property strategy What additional indications and therapies Compass Pathways is interested in Lin...
Scaling Psilocybin Therapy: Compass Pathways' Lars Wilde
August 13, 2021 17:00 - 59 minutes - 41.2 MBEpisode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways, a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression. In this episode, we discuss: Lars’ experience overcoming Treatment-Resistant Depression with psilocybin The nuances of clinical trials and psilocybin dosing protocols Compass Pathways’ Intellectual Property strategy What additional indications and therapies Compass Pathways is interested in Lin...